Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin
CA 2450828 C · Owner: Agen Biomedical Limited · Inventors: Carr, Francis J.; Hamilton, Anita A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to humanised forms of the mouse monoclonal antibody DD-3B6/22. This antibody is specific for D-dimer a degradation , fragment of crosslinked fibrin polymers. The invention also includes the use of these antibodies to detect blood clots in vivo.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 26, 2002 and granted November 26, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 26, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 26, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.